Project Grant HT9425261E084
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- Federal Grant Award Summary Award Details: Transposon Therapeutics, Inc. received a $1.92 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2026, with an ultimate completion date of February 14, 2028. The project, titled "Development of Human Line-1 Reverse Transcriptase Inhibitors for the Treatment of Amyotrophic Lateral Sclerosis," will be conducted in Laguna Niguel, California. Deliverables...
- Federal Grant Award Summary Wayfinder Biosciences Inc. received a $680,591 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel small molecule screening approach for direct and selective targeting of repeat expansion RNA in C9ORF72 Amyotrophic Lateral Sclerosis (ALS). The award, issued on June 15, 2025, with a completion date of December 14, 2026, funds hypothesis-driven biomedical research...
- Federal Project Grant Award Summary Meso Scale Diagnostics LLC (doing business as Meso Scale Discovery) received a $997,807 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award supports the development of ultrasensitive immunoassays for detecting TDP-43 pathology, a biomarker associated with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). This...
- Federal Project Grant Award Summary Sanford Burnham Prebys Medical Discovery Institute received a $1,078,882 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2025, through April 30, 2027. The award supports research applying chemical engineering approaches to amyotrophic lateral sclerosis (ALS) treatment, with a focus on advancing understanding of the multimodal therapeutic actions of donor and host neural...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $939,325 to the Weizmann Institute of Science on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support the GLOBALS (Global Omic Biomarker Research for ALS) initiative. This three-year project, extending through October 31, 2028, funds advanced biomedical research focused on discovering and developing omic biomarkers for amyotrophic lateral sclerosis (ALS). The research...
- Federal Project Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine received a $999,999 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 1, 2026. The award funds research titled "Schwann Cell-Derived Extracellular Vesicle Platform for ALS Biomarker Discovery in Biofluids" with a completion date of May 31, 2029. This project delivers biomarker discovery research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Methodist Hospital Research Institute a $998,039 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a large-scale multiomic study identifying systemic and central immune-related biomarkers in amyotrophic lateral sclerosis (ALS). The three-year research initiative, commencing May 1, 2026 and concluding April 30, 2029, will be performed at the institute's Houston, Texas...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $840,000 to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center under the Military Medical Research and Development program (CFDA 12.420) for the project "Targeting M6A Dysregulation in ALS via Small Molecule Approaches." The award, effective July 1, 2026, through June 30, 2028, supports research and development activities focused on investigating therapeutic interventions for...
- Federal Project Grant Award Summary The Defense Health Agency awarded Columbia University's Health Sciences Division a $2.8 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a pilot clinical trial of NL-CHCHD-001, a novel antisense oligonucleotide therapeutic, in patients with CHCHD10-associated amyotrophic lateral sclerosis. The award, effective June 1, 2026, through May 31, 2029, supports clinical investigation and translational research...
- Federal Grant Award Summary New York University School of Medicine received a $1.0 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from June 1, 2026, through May 31, 2029. The award funds research into diffusion magnetic resonance imaging (MRI) biomarkers of axonal degeneration in amyotrophic lateral sclerosis (ALS). This research initiative will advance understanding of neurodegeneration...